Japan-based Asahi Kasei Corporation (TSE: 3407; OTC: AHKSY) has completed its acquisition of Germany-based Aicuris Anti-infective Cures AG, a privately held biopharmaceutical company, adding three antiviral assets to its specialty pharmaceutical portfolio. The transaction positions Asahi Kasei to deploy Aicuris's infectious disease pipeline through its US transplant medicine subsidiary, Veloxis Pharmaceuticals, Inc., targeting immunocompromised patient populations where nucleoside analogue resistance represents a persistent clinical gap.
Asahi previously reported that the transaction price tag totals around EUR 780 million (USD 919 million). The Japanese firm projects Aicuris-derived revenue will reach USD 500 million by 2030, excluding the BK virus candidate AIC468. The company expects the acquisition to contribute positively to operating income from fiscal year 2028 onward, after amortization of goodwill and intangible assets. The deal conveys global rights across all three assets, with the structural distinction that Prevymis (letermovir) royalty income flows from worldwide sales under a pre-existing exclusive commercialization license held by Merck/MSD.
Pritelivir and the helicase-primase inhibitor mechanism
The near-term commercial catalyst is pritelivir, a small-molecule HSV helicase-primase inhibitor targeting immunocompromised patients with acyclovir-resistant or treatment-resistant mucocutaneous HSV-1 and HSV-2 infections. Unlike nucleoside analogues such as acyclovir and foscarnet, which target viral DNA polymerase, pritelivir inhibits the helicase-primase complex — a distinct enzymatic machinery required for HSV DNA unwinding and primer synthesis — thereby retaining activity in polymerase-mutant resistant strains. The US FDA has granted Priority Review to the pritelivir New Drug Application, with a Prescription Drug User Fee Act target date in Q4 2026. Asahi Kasei estimates the addressable US population at approximately 15,000 immunocompromised patients, with projected second-line market penetration approaching 70%, and peak revenue exceeding USD 400 million in the mid- to late 2030s.